This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Victor M. Rivera, MD
Houston Neurological Center Total Health Care Center of the Methodist Hospital 6560 Fannin, Suite 1224 Houston, TX 77030

Arch Neurol. 1989;46(7):718.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—Nelson's review¹ leaves many aspects uncovered and omits pertinent data that have been helpful for advocates who believe that intrathecal methylprednisolone acetate (Depo-Medrol) does have a safe role in the symptomatic management of lower limb spasticity in multiple sclerosis. I shall not address claims of effective epidural therapy in patients with radiculopathy.

The article fails to mention previous discussions in similar forum^2,3 and data from our own studies⁴ in which 100 patients with multiple sclerosis, with severe spastic paraparesis not responsive to common pharmacologic agents, were given 285 intrathecal injections of 80 mg of methylprednisolone acetate given each at 3- to 6- month intervals, with an average of 3.02 injections per patient per 24 months. By adhering to simple criteria for indications (spasticity, incapacitating clonus, gait, and sphincter dysfunction) . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?